British Journal of Cancer Management

This item requires a subscription.

Bortezomib combination therapy for multiple myeloma
BJCM, Volume 2, Number 2.

Multiple myeloma (MM) treated by conventional therapies is currently an incurable disease with a median survival of three to four years.1 Recently, the increased understanding of the pathogenesis of MM has led to the introduction of novel agents such as lenalidomide (Revlimid®, Celgene Corporation, USA) and the proteasome inhibitor, bortezomib (Velcade®, Ortho Biotech, UK).

To view this item, select one of the options below:

	Purchase access
	In order to view articles you will need to pay a subscription for 24-hour access. You can view all articles on this site during the subscription period. Please click here to subscribe.

	Sign in
	If you are already have a subscription, please sign in here.
	email address
	Password
	Forgotten your password?

	Important
	All the articles are in PDF format.
	To view the articles you will need Adobe Acrobat Reader.
	To download a copy, free of charge, please click here.

	Help
	If you need help accessing this site, please click here.

The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the sponsors, publisher, Editor or Editorial Board. Accordingly the sponsors, publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.
Copyright (©) 2010 Hayward Group Ltd. The title British Journal of Cancer Management is the property of Hayward Group Ltd and, together with the content, is bound by copyright. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to: admin@hayward.co.uk